GIP and GLP-1 receptor co-agonist
Bgm050 sc
BGM050_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.45 (0.01 to 32.98) | 0.62 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 4.67 (0.32 to 136) | 0.17 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.42 (0.14 to 119) | 0.32 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 21.49 (5.17 to 163) | 0.01 |